MX389563B - Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias. - Google Patents

Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.

Info

Publication number
MX389563B
MX389563B MX2018010781A MX2018010781A MX389563B MX 389563 B MX389563 B MX 389563B MX 2018010781 A MX2018010781 A MX 2018010781A MX 2018010781 A MX2018010781 A MX 2018010781A MX 389563 B MX389563 B MX 389563B
Authority
MX
Mexico
Prior art keywords
treatment
dosage regimen
inflammatory conditions
acute exacerbations
exacerbations
Prior art date
Application number
MX2018010781A
Other languages
English (en)
Spanish (es)
Other versions
MX2018010781A (es
Inventor
Colin Orford
Colm Farrell
Cyril Clarke
Jacqueline Parkin
Buck Stefan De
Original Assignee
Mereo Biopharma 1 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Ltd filed Critical Mereo Biopharma 1 Ltd
Publication of MX2018010781A publication Critical patent/MX2018010781A/es
Publication of MX389563B publication Critical patent/MX389563B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018010781A 2016-03-08 2016-03-08 Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias. MX389563B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2016/050635 WO2017153701A1 (en) 2016-03-08 2016-03-08 Dosage regimen for the treatment of acute exacerbations of inflammatory conditions

Publications (2)

Publication Number Publication Date
MX2018010781A MX2018010781A (es) 2018-11-09
MX389563B true MX389563B (es) 2025-03-20

Family

ID=55646778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010781A MX389563B (es) 2016-03-08 2016-03-08 Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.

Country Status (9)

Country Link
US (1) US10617674B2 (enExample)
JP (1) JP6741773B2 (enExample)
KR (1) KR20180119597A (enExample)
AU (1) AU2016397046B2 (enExample)
BR (1) BR112018067784A2 (enExample)
CA (1) CA3016368A1 (enExample)
MX (1) MX389563B (enExample)
RU (1) RU2709509C1 (enExample)
WO (1) WO2017153701A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385717B (es) * 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
JP7280627B2 (ja) * 2017-12-11 2023-05-24 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
RU2381219C2 (ru) * 2003-06-26 2010-02-10 Новартис Аг ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US20050277602A1 (en) * 2004-05-21 2005-12-15 Grunstein Michael M Methods employing agonists of P38 map kinase for the treatment of asthma
US20090270350A1 (en) * 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
LT2827860T (lt) * 2012-03-20 2016-12-12 Mereo Biopharma 1 Limited Pirazolo darinio panaudojimas stiprių lėtinės obstrukcinės plaučių ligos paūmėjimų gydymui

Also Published As

Publication number Publication date
JP2019507785A (ja) 2019-03-22
MX2018010781A (es) 2018-11-09
RU2709509C1 (ru) 2019-12-18
US10617674B2 (en) 2020-04-14
WO2017153701A1 (en) 2017-09-14
JP6741773B2 (ja) 2020-08-19
AU2016397046A1 (en) 2018-09-06
AU2016397046B2 (en) 2022-05-12
US20190091203A1 (en) 2019-03-28
CA3016368A1 (en) 2017-09-14
BR112018067784A2 (pt) 2019-01-15
KR20180119597A (ko) 2018-11-02

Similar Documents

Publication Publication Date Title
FR21C1048I2 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3722274T3 (da) 2-perfluorbutylpentan til oftalmisk indgivelse
LT3139925T (lt) Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus
UY35972A (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
EP3458060C0 (en) COMBINATION THERAPY FOR MALE SEXUAL DYSFUNCTION
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
MX385717B (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
MX389563B (es) Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
PL3226888T3 (pl) Podawanie selektywnego transsygnałowego inhibitora IL-6
PL3368015T3 (pl) Dostarczanie niesteroidowego leku przeciwzapalnego o przedłużonym uwalnianiu
EP3579855A4 (en) ANTI-PATHOGENIC THERAPEUTIC COMPOSITIONS
EP3375456A4 (en) TOPICALLY APPLIED MEDICINE WITH DELAYED RELEASE
EP3431079C0 (en) COMPRESSED
CL2017000026A1 (es) Formas de dosificación farmacéutica
LT3244889T (lt) Farmacinė kompozicija, skirta mikozės gydymui
DK3484543T3 (da) Lægemiddelleveringssystem
DK3270923T3 (da) Terapeutisk middel til frontallapsdysfunktion
DK3229868T3 (da) Lægemiddeladministrationsanordning, der omfatter en prisme
PT3866775T (pt) Cisteamina para utilização no tratamento de doenças pulmonares